Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...

Labroots is excited to announce our 14th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2026 held on May 13th, 2026! The Precision Medicine: Genomics, ...

The majority of rare diseases have a genetic cause. The underlying genetic alteration can be found more and more easily, for example by means of exome sequencing (ES), leading to a molecular genetic ...

Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved ...

Labroots is excited to announce our 13th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2025 held on May 14th, 2025! The Precision Medicine: Genomics, ...

Renal tumor pathology has evolved considerably, expanding from two main types of renal malignant tumors to over 20 distinct types. Diagnostic criteria have advanced from purely morphological features ...

The Southern blot, which detects specific DNA sequences, was one of the first molecular diagnostic methods to be widely adopted. 2 This type of probe-based assay uses a single-stranded oligonucleotide ...

The Achromatopsia Market is experiencing substantial growth, expected to increase from USD 121.99 million in 2026 to USD 191.22 million by 2032 at a compound annual growth rate of ...

Integration of AI with image-based genomics, consolidation towards integrated platforms, and growing focus on companion diagnostics bolster growthDublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The ...

Fulgent Genetics agrees to buy StrataDx and assets from Bako Diagnostics for $55.5 million. Learn how this cash deal expands ...